In recent years, drugs that inhibit CDK4/6 activity (palbociclib, ribociclib, or abemaciclib [10,11,12,13]) in combination with endocrine therapy have been used to treat patients with ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Here, CDK4 is linked to breast cancer.